Evidence map›Paper›PMID 35444961›Full record

ReviewFrontiers in cellular and infection microbiology2022

Advancing a Human Onchocerciasis Vaccine From Antigen Discovery to Efficacy Studies Against Natural Infection of Cattle With

Bin Zhan, Maria Elena Bottazzi, Peter J Hotez, Sara Lustigman

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in cellular and infection microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Procedure for Handling and Storage ofTropical medicine and infectious disease · 2023
    Article
  10. Review
  11. Review
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Bin ZhanTexas Children's Hospital Center for Vaccine Development, Baylor College of Medicine, Houston, TX, United States.
Maria Elena BottazziTexas Children's Hospital Center for Vaccine Development, Baylor College of Medicine, Houston, TX, United States.
Peter J HotezTexas Children's Hospital Center for Vaccine Development, Baylor College of Medicine, Houston, TX, United States.
Sara LustigmanLaboratory of Molecular Parasitology, Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY, United States.
Texas Children's Hospital · USNew York Blood Center · US

Funding

The development of a recombinant vaccine against human onchocerciasisR01AI078314 · NIAID · NEW YORK BLOOD CENTER · PI LUSTIGMAN, SARA · 2009 to 2021
$7.0M
NIAID NIH HHS R01 AI078314
6 · The paper itself

Abstract

Human onchocerciasis is a devastating neglected tropical disease caused by infection of the filarial nematode

Indexed as

Intestinal VolvulusOnchocerciasisVaccinesAnimalsBlindnessCattleHumansIvermectinOnchocercaIvermectinVaccinesanimal modelclinical trialOnchocerca volvulusonchocerciasisvaccine

Identifiers

PMID35444961
PMCPMC9015098
OpenAlexW4225332509

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.